BeOne Medicines, Ltd. American Depositary Receipt (ONC)
Market Closed
11 Jun, 20:00
$
260. 27
-3.34
-1.267%
Pre Market
$
+24.73 +9.5017% 285. 00
28.17B Market Cap
- P/E Ratio
- Div Yield
492,445 Volume
-5.11 Eps
$ 263.61
Previous Close Want to track ONC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple
Cancer stock BeiGene renamed itself as BeOne. Shares have gained 40% year to date, outperforming the S&P 500.
Investors | 1 year ago
BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field
Zanubrutinib is currently best-in-class among BTK inhibitors for CLL, with superior efficacy and safety over ibrutinib and strong market momentum. Zanubrutinib will be in the leading position in CLL in the next 5 years, given the best-in-class BTK inhibitor and potential best combined regimen of zanubrutinib plus sonrotoclax in 2027. Pirtobrutinib maybe a powerful competitor to zanubrutinib when the phase 3 BRUIN CLL-314 trial PFS data is available in 2027.
Seekingalpha | 1 year ago
The Billionaire Baker Brothers Just Made This Big Biotech Stock Move
If you're interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to.
247wallst | 1 year ago
